86: Hematopoietic stem cell transplantation (HCT) for autoimmune diseases (AI)
Peter A. McSweeney(Mesoblast (United States)), Harry Atkins(University of Ottawa), Christopher Bredeson, Mary M. Horowitz(Medical College of Wisconsin), M. Kukreja(Medical College of Wisconsin), Marcelo C. Pasquini(Cleveland Clinic), Richard A. Nash(Colorado Blood Cancer Institute)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k